US Patent Issued to United Therapeutics on May 27 for "Treatment of pulmonary arterial hypertension with prostacyclin-treated endothelial progenitor cells" (North Carolina Inventors)

ALEXANDRIA, Va., June 17 -- United States Patent no. 12,310,992, issued on May 27, was assigned to United Therapeutics Corp. (Silver Spring, Md.).

"Treatment of pulmonary arterial hypertension with prostacyclin-treated endothelial progenitor cells" was invented by Roger Jeffs (Chapel Hill, N.C.), Thomas Petersen (Durham, N.C.), Roger M. Ilagan (Burlington, N.C.) and Michael Wade (Chapel Hill, N.C.).

According to the abstract* released by the U.S. Patent & Trademark Office: "The current application is directed to a method for treating pulmonary arterial hypertension (PAH), comprising: providing isolated endothelial progenitor cells (EPCs); treating the EPCs with prostacyclin, wherein the treated EPCs exhibit a hyperproliferative phenotype ...